<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609466</url>
  </required_header>
  <id_info>
    <org_study_id>574139</org_study_id>
    <nct_id>NCT00609466</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group, Multi-center, Active- and Placebo-controlled Trial to Evaluate the Analgesic Efficacy and Safety of Multiple Doses of CG5503 IR for Postoperative Pain Following Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grünenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grünenthal GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to demonstrate the efficacy and safety of multiple-dose
      application of oral application of CG5503 IR 75mg compared to placebo and to assess safety
      and tolerability of CG5503 IR 75mg in subjects following bunionectomy.

      This trial was performed based on a previously performed double-blind, placebo-controlled,
      multiple-dose trial in the same indication investigating 3 dose strengths CG5503 IR (50, 75
      and 100 mg) published under PMID: 18851776.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects undergoing bunionectomy often experience moderate to severe acute pain post-surgery.
      Normally such pain is controlled when subjects receive repeated doses of opioid analgesics.
      However, opioid therapy is commonly associated with side effects such as nausea, vomiting,
      sedation, constipation, addiction, tolerance, and respiratory depression. CG5503, a newly
      synthesized drug with an immediate release (IR) formulation, also acts as a centrally acting
      pain reliever but has a dual mode of action. The aim of this trial is to investigate the
      effectiveness (level of pain control) and safety (side effects) of CG5503 IR 75mg compared
      with no drug (placebo) or one dose of morphine (an opioid commonly used to treat
      post-surgical pain). This trial is a randomized, double-blind (neither investigator nor
      patient will know which treatment was received), active- and placebo-controlled,
      parallel-group, multicenter trial to evaluate the treatment of acute pain after bunionectomy.
      The trial will include a blinded 72 hour inpatient phase immediately following bunionectomy,
      during which subjects will be treated with either 75-mg CG5503 IR, a placebo, or 30-mg
      morphine, and pain relief will be periodically assessed. Assessments of pain relief include
      the pain intensity numeric rating scale (PI), pain relief numeric rating scale (PAR), and
      patient global impression of change scale (PGIC). Safety evaluations include monitoring of
      adverse events, physical examinations, and clinical laboratory tests. Venous blood samples
      will be collected for the determination of serum concentrations of CG5503 and morphine. The
      alternative trial hypothesis is that at least 1 dose strength of CG5503 will be different
      from placebo in controlling pain at 48 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity.</measure>
    <time_frame>Baseline value to 48 hours after first study drug intake.</time_frame>
    <description>Pain Intensity assessed at predefined time points over a 48 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID48) is from -480 (indicative of an increase in pain) to 480 (indicative of a decrease in pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Using Rescue Medication</measure>
    <time_frame>Baseline up to 72 hours after first study drug intake</time_frame>
    <description>Number of participants who used at least one dose of rescue medication during the 72 hour double blind period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief (TOTPAR)</measure>
    <time_frame>Baseline to 48 hours after first study drug intake</time_frame>
    <description>Total pain relief (TOTPAR) in the 48 hour period from the first dose of study drug. The subject was to indicate pain relief at rest in response to the following question: How much relief have you had from your starting pain? None = 0, A little = 1, Some = 2, A lot = 3 and Complete = 4. The theoretical maximum range of Total pain relief (TOTPAR)48 is from 0 (indicative of no pain relief) to 192. The higher the value the better the pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Differences Over 6 Hours (SPID6) Relative to the Baseline Pain Intensity</measure>
    <time_frame>Baseline to 6 hours after intake of first study drug</time_frame>
    <description>Pain Intensity assessed at predefined time points over a 6 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID6) is from -60 (indicative of an increase in pain) to 60 (indicative of a decrease in pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Differences Over 12 Hours (SPID12) Relative to the Baseline Pain Intensity</measure>
    <time_frame>Baseline to 12 hours after first study drug intake</time_frame>
    <description>Pain Intensity assessed at predefined time points over a 12 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID12) is from -120 (indicative of an increase in pain) to 120 (indicative of a decrease in pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Differences Over 24 Hours (SPID24) Relative to the Baseline Pain Intensity</measure>
    <time_frame>Baseline to 24 hours after first study drug intake</time_frame>
    <description>Pain Intensity assessed at predefined time points over a 24 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID24) is from -240 (indicative of an increase in pain) to 240 (indicative of a decrease in pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Differences Over 72 Hours (SPID72) Relative to the Baseline Pain Intensity</measure>
    <time_frame>Baseline to 72 hours after first intake of study drug</time_frame>
    <description>Pain Intensity assessed at predefined time points over a 72 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID72) is from -720 (indicative of an increase in pain) to 720 (indicative of a decrease in pain).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">291</enrollment>
  <condition>Bunionectomy</condition>
  <condition>Pain</condition>
  <condition>Postoperative Pain</condition>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CG5503 IR 75mg 4 to 6 hourly for 72 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine IR 30 mg 4 to 6 hourly for 72 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo 4 to 6 hourly for 72 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG5503 IR</intervention_name>
    <description>75mg IR 4 - 6 hourly Total: 72 hours</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine 30 mg IR 4 - 6 hourly Total: 72 hours</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo; 4 - 6 hourly; Total: 72 hours</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects between 18 and 80 years of age;

          -  Scheduled to undergo primary unilateral first metatarsal bunionectomy;

          -  Anesthesiological and surgical procedures performed according to protocol;

          -  Moderate or severe baseline pain following bunionectomy on a VRS within 9 hours of
             termination of the continuous popliteal sciatic block or systemic analgesia;

          -  Pain following bunionectomy of at least 4 on an 11-point NRS within 9 hours of
             termination of the continuous popliteal sciatic block or systemic analgesia; American
             Society of Anesthesiologists (ASA) classification I-III.

        Exclusion Criteria:

          -  History of seizure disorder;

          -  History of alcohol, medication or drug dependency, unstable psychological personality
             requiring intermittent or permanent treatment; severely impaired renal function,
             moderately or severely impaired hepatic function;

          -  Contraindications to, or history of allergy or hypersensitivity to CG5503, oxycodone,
             morphine, fentanyl hydrocodone, acetaminophen, heparin, or any compound planned to be
             used during the anesthesia, or their excipients;

          -  Pre-operative use within 12h prior to surgery or peri-operative use of non- steroidal
             anti-inflammatory drugs (NSAIDs);

          -  Treated regularly with opioid analgesic or NSAIDs within 30 days prior to screening;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen E Daniels, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Premier Research Group (formerly SCIREX Corporation)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 104</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 105</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 106</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <results_first_submitted>September 16, 2009</results_first_submitted>
  <results_first_submitted_qc>October 22, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2009</results_first_posted>
  <last_update_submitted>November 10, 2011</last_update_submitted>
  <last_update_submitted_qc>November 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid</keyword>
  <keyword>Central acting analgesic</keyword>
  <keyword>CG5503 IR</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Bunionectomy</keyword>
  <keyword>Morphine</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period for this in-patient, multicenter study occurred between 04 September 2007 and 11 December 2007.</recruitment_details>
      <pre_assignment_details>The trial consisted of a Screening Period (Day -28 up to the first surgical incision on Day -1), a Surgical Period (Day -1 to Day 1 at approximately 03:00 h.), a Qualification Period (Day 1), a Double-Blind Treatment Period (Day 1 up to Day 4), and a Follow-up Period (Day 8 up to Day 18).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CG5503</title>
          <description>CG5503 IR 75mg 4-6 hourly</description>
        </group>
        <group group_id="P2">
          <title>Morphine</title>
          <description>Morphine IR 30mg 4 to 6 hourly</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching Placebo 4 to 6 hourly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CG5503</title>
          <description>CG5503 IR 75mg 4-6 hourly</description>
        </group>
        <group group_id="B2">
          <title>Morphine</title>
          <description>Morphine IR 30mg 4 to 6 hourly</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching Placebo 4 to 6 hourly</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="291"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="12.58"/>
                    <measurement group_id="B2" value="43.7" spread="14.19"/>
                    <measurement group_id="B3" value="43.8" spread="13.93"/>
                    <measurement group_id="B4" value="44.0" spread="13.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity.</title>
        <description>Pain Intensity assessed at predefined time points over a 48 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID48) is from -480 (indicative of an increase in pain) to 480 (indicative of a decrease in pain).</description>
        <time_frame>Baseline value to 48 hours after first study drug intake.</time_frame>
        <population>Intention to Treat - randomized subjects who were dosed and had a baseline pain intensity assessment. Last observation carried forward was used.</population>
        <group_list>
          <group group_id="O1">
            <title>CG5503</title>
            <description>CG5503 IR 75mg 4-6 hourly</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>Morphine IR 30mg 4 to 6 hourly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo 4 to 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity.</title>
          <description>Pain Intensity assessed at predefined time points over a 48 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID48) is from -480 (indicative of an increase in pain) to 480 (indicative of a decrease in pain).</description>
          <population>Intention to Treat - randomized subjects who were dosed and had a baseline pain intensity assessment. Last observation carried forward was used.</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" spread="130.83"/>
                    <measurement group_id="O2" value="102.5" spread="153.26"/>
                    <measurement group_id="O3" value="-17.5" spread="111.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no treatment difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariate.</method_desc>
            <param_type>Least square mean</param_type>
            <param_value>70.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>35.9</ci_lower_limit>
            <ci_upper_limit>105.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Using Rescue Medication</title>
        <description>Number of participants who used at least one dose of rescue medication during the 72 hour double blind period.</description>
        <time_frame>Baseline up to 72 hours after first study drug intake</time_frame>
        <population>Intention to treat (ITT) and Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>CG5503</title>
            <description>CG5503 IR 75mg 4-6 hourly</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>Morphine IR 30mg 4 to 6 hourly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo 4 to 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Using Rescue Medication</title>
          <description>Number of participants who used at least one dose of rescue medication during the 72 hour double blind period.</description>
          <population>Intention to treat (ITT) and Last Observation Carried Forward (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Test for time (in hours) to first rescue medication use. No multiplicity adjustment.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Adjusted for site</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pain Relief (TOTPAR)</title>
        <description>Total pain relief (TOTPAR) in the 48 hour period from the first dose of study drug. The subject was to indicate pain relief at rest in response to the following question: How much relief have you had from your starting pain? None = 0, A little = 1, Some = 2, A lot = 3 and Complete = 4. The theoretical maximum range of Total pain relief (TOTPAR)48 is from 0 (indicative of no pain relief) to 192. The higher the value the better the pain relief.</description>
        <time_frame>Baseline to 48 hours after first study drug intake</time_frame>
        <population>Intention to treat(ITT)and Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>CG5503</title>
            <description>CG5503 IR 75mg 4-6 hourly</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>Morphine IR 30mg 4 to 6 hourly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo 4 to 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pain Relief (TOTPAR)</title>
          <description>Total pain relief (TOTPAR) in the 48 hour period from the first dose of study drug. The subject was to indicate pain relief at rest in response to the following question: How much relief have you had from your starting pain? None = 0, A little = 1, Some = 2, A lot = 3 and Complete = 4. The theoretical maximum range of Total pain relief (TOTPAR)48 is from 0 (indicative of no pain relief) to 192. The higher the value the better the pain relief.</description>
          <population>Intention to treat(ITT)and Last Observation Carried Forward (LOCF)</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="49.63"/>
                    <measurement group_id="O2" value="81.6" spread="56.30"/>
                    <measurement group_id="O3" value="41.8" spread="50.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no treatment difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment used</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariate.</method_desc>
            <param_type>Least square mean</param_type>
            <param_value>37.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>22.7</ci_lower_limit>
            <ci_upper_limit>52.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Intensity Differences Over 6 Hours (SPID6) Relative to the Baseline Pain Intensity</title>
        <description>Pain Intensity assessed at predefined time points over a 6 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID6) is from -60 (indicative of an increase in pain) to 60 (indicative of a decrease in pain).</description>
        <time_frame>Baseline to 6 hours after intake of first study drug</time_frame>
        <population>Intention to treat(ITT) and Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>CG5503</title>
            <description>CG5503 IR 75mg 4-6 hourly</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>Morphine IR 30mg 4 to 6 hourly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo 4 to 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Differences Over 6 Hours (SPID6) Relative to the Baseline Pain Intensity</title>
          <description>Pain Intensity assessed at predefined time points over a 6 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID6) is from -60 (indicative of an increase in pain) to 60 (indicative of a decrease in pain).</description>
          <population>Intention to treat(ITT) and Last Observation Carried Forward (LOCF).</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="13.51"/>
                    <measurement group_id="O2" value="8.0" spread="15.59"/>
                    <measurement group_id="O3" value="-1.2" spread="13.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no treatment difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariate.</method_desc>
            <param_type>Least square means</param_type>
            <param_value>9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.2</ci_lower_limit>
            <ci_upper_limit>13.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Intensity Differences Over 12 Hours (SPID12) Relative to the Baseline Pain Intensity</title>
        <description>Pain Intensity assessed at predefined time points over a 12 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID12) is from -120 (indicative of an increase in pain) to 120 (indicative of a decrease in pain).</description>
        <time_frame>Baseline to 12 hours after first study drug intake</time_frame>
        <population>Intention to treat (ITT) and Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>CG5503</title>
            <description>CG5503 IR 75mg 4-6 hourly</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>Morphine IR 30mg 4 to 6 hourly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo 4 to 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Differences Over 12 Hours (SPID12) Relative to the Baseline Pain Intensity</title>
          <description>Pain Intensity assessed at predefined time points over a 12 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID12) is from -120 (indicative of an increase in pain) to 120 (indicative of a decrease in pain).</description>
          <population>Intention to treat (ITT) and Last Observation Carried Forward (LOCF).</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="28.89"/>
                    <measurement group_id="O2" value="17.9" spread="32.12"/>
                    <measurement group_id="O3" value="-4.7" spread="24.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no treatment difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariate.</method_desc>
            <param_type>Least square mean</param_type>
            <param_value>20.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>13.2</ci_lower_limit>
            <ci_upper_limit>28.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Intensity Differences Over 24 Hours (SPID24) Relative to the Baseline Pain Intensity</title>
        <description>Pain Intensity assessed at predefined time points over a 24 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID24) is from -240 (indicative of an increase in pain) to 240 (indicative of a decrease in pain).</description>
        <time_frame>Baseline to 24 hours after first study drug intake</time_frame>
        <population>Intention to treat (ITT)and Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>CG5503</title>
            <description>CG5503 IR 75mg 4-6 hourly</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>Morphine IR 30mg 4 to 6 hourly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo 4 to 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Differences Over 24 Hours (SPID24) Relative to the Baseline Pain Intensity</title>
          <description>Pain Intensity assessed at predefined time points over a 24 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID24) is from -240 (indicative of an increase in pain) to 240 (indicative of a decrease in pain).</description>
          <population>Intention to treat (ITT)and Last Observation Carried Forward (LOCF).</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="60.17"/>
                    <measurement group_id="O2" value="41.3" spread="68.96"/>
                    <measurement group_id="O3" value="-10.7" spread="51.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no treatment difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariate.</method_desc>
            <param_type>Least square mean</param_type>
            <param_value>36.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>20.7</ci_lower_limit>
            <ci_upper_limit>52.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Intensity Differences Over 72 Hours (SPID72) Relative to the Baseline Pain Intensity</title>
        <description>Pain Intensity assessed at predefined time points over a 72 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID72) is from -720 (indicative of an increase in pain) to 720 (indicative of a decrease in pain).</description>
        <time_frame>Baseline to 72 hours after first intake of study drug</time_frame>
        <population>Intention to treat (ITT) and Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>CG5503</title>
            <description>CG5503 IR 75mg 4-6 hourly</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>Morphine IR 30mg 4 to 6 hourly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo 4 to 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Differences Over 72 Hours (SPID72) Relative to the Baseline Pain Intensity</title>
          <description>Pain Intensity assessed at predefined time points over a 72 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID72) is from -720 (indicative of an increase in pain) to 720 (indicative of a decrease in pain).</description>
          <population>Intention to treat (ITT) and Last Observation Carried Forward (LOCF).</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4" spread="212.05"/>
                    <measurement group_id="O2" value="174.1" spread="242"/>
                    <measurement group_id="O3" value="-19.1" spread="179.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no treatment difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>No multiplicity adjustment used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariate.</method_desc>
            <param_type>Least square means</param_type>
            <param_value>108.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>51.9</ci_lower_limit>
            <ci_upper_limit>164.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CG5503</title>
          <description>CG5503 IR 75mg 4-6 hourly</description>
        </group>
        <group group_id="E2">
          <title>Morphine</title>
          <description>Morphine IR 30mg 4 to 6 hourly</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching Placebo 4 to 6 hourly</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens Johnson Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69"/>
                <counts group_id="E2" subjects_affected="85"/>
                <counts group_id="E3" subjects_affected="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="79" subjects_affected="46" subjects_at_risk="96"/>
                <counts group_id="E2" events="147" subjects_affected="65" subjects_at_risk="96"/>
                <counts group_id="E3" events="34" subjects_affected="24" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="40" subjects_affected="21" subjects_at_risk="96"/>
                <counts group_id="E2" events="156" subjects_affected="56" subjects_at_risk="96"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Gamma glutamyl transferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="62" subjects_affected="29" subjects_at_risk="96"/>
                <counts group_id="E2" events="39" subjects_affected="23" subjects_at_risk="96"/>
                <counts group_id="E3" events="25" subjects_affected="17" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="27" subjects_affected="19" subjects_at_risk="96"/>
                <counts group_id="E2" events="38" subjects_affected="28" subjects_at_risk="96"/>
                <counts group_id="E3" events="32" subjects_affected="24" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="29" subjects_affected="15" subjects_at_risk="96"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="96"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Grünenthal GmbH reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither Grünenthal nor the investigator has the right to prohibit publication unless publication can be shown to affect possible patent rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lortab (hydrocodone/acetaminophen) was allowed as rescue medication.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>René Allard</name_or_title>
      <organization>Grunenthal</organization>
      <phone>49 241 569 3223</phone>
      <email>Clinical-Trials@grunenthal.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

